Skip navigation
  •  Inicio
  • UDC 
    • Cómo depositar
    • Políticas do RUC
    • FAQ
    • Dereitos de Autor
    • Máis información en INFOguías UDC
  • Percorrer 
    • Comunidades
    • Buscar por:
    • Data de publicación
    • Autor
    • Título
    • Materia
  • Axuda
    • español
    • Gallegan
    • English
  • Acceder
  •  Galego 
    • Español
    • Galego
    • English
  
Ver ítem 
  •   RUC
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • Ver ítem
  •   RUC
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry

Thumbnail
Ver/abrir
Kaplon_Comprehensible.pdf (8.284Mb)
Kaplon_Comprehensible_AppS1.pdf - Appendix S1 (134.9Kb)
Kaplon_Comprehensible_AppS2.pdf - Appendix S2 (326.6Kb)
Kaplon_Comprehensible_FigS1.pdf - Figure S1 (16.92Kb)
Kaplon_Comprehensive_FigS2.zip - Figure S2 (61.73Kb)
Kaplon_Comprehensible_TableS1.pdf - Table S1 (103.3Kb)
Kaplon_Comprehensible_TableS2.pdf - Table S2 (103.8Kb)
Use este enlace para citar
http://hdl.handle.net/2183/29406
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
A non ser que se indique outra cousa, a licenza do ítem descríbese como Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
Coleccións
  • Investigación (FCS) [1293]
Metadatos
Mostrar o rexistro completo do ítem
Título
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry
Autor(es)
Kaplon-Cieslicka, Agnieszka
Benson, Lina
Chioncel, Ovidiu
Crespo-Leiro, María Generosa
Coats, Andrew J.S.
Anker, Stefan
Filippatos, Gerasimos
Ruschitzka, Frank
Hage, Camilla
Drozdz, Jaroslaw
Seferovic, Petar M.
Rosano, Giuseppe
Piepoli, Massimo
Mebazaa, Alexandre
McDonagh, Theresa
Lainscak, Mitja
Savarese, Gianluigi
Ferrari, Roberto
Maggioni, Aldo P.
Lund, Lars H.
Data
2021-12-27
Cita bibliográfica
Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drożdż J, Seferovic P, Rosano GMC, Piepoli M, Mebazaa A, McDonagh T, Lainscak M, Savarese G, Ferrari R, Maggioni AP, Lund LH; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022 Feb;24(2):335-350.
Resumo
[Abstract] Aims: To perform a comprehensive characterization of acute heart failure (AHF) with preserved (HFpEF), versus mildly reduced (HFmrEF) versus reduced ejection fraction (HFrEF). Methods and results: Of 5951 participants in the ESC HF Long-Term Registry hospitalized for AHF (acute coronary syndromes excluded), 29% had HFpEF, 18% HFmrEF, and 53% HFrEF. Hospitalization reasons were most commonly atrial fibrillation (more in HFmrEF and HFpEF), followed by ischaemia (HFmrEF), infection (HFmrEF and HFpEF), worsening renal function (HFrEF), and uncontrolled hypertension (HFmrEF and HFpEF). Hospitalization characteristics included lower blood pressure, more oedema and higher natriuretic peptides with lower ejection fraction, similar pulmonary congestion, more mitral regurgitation in HFrEF and HFmrEF and more tricuspid regurgitation in HFrEF. In-hospital mortality was 3.4% in HFrEF, 2.1% in HFmrEF and 2.2% in HFpEF. Intravenous diuretic (∼80%) and nitrate (∼15%) use was similar but inotrope use greater in HFrEF (16%, vs. HFmrEF 7.4% vs. HFpEF 5.3%). Weight loss and estimated glomerular filtration rate improvement were greater in HFrEF, whereas reduction in natriuretic peptides was similar. Over 1 year post-discharge, events per 100 patient-years (95% confidence interval) in HFrEF versus HFmrEF versus HFpEF were: all-cause death 22 (20-24) versus 17 (14-20) versus 17 (15-20); cardiovascular (CV) death 12 (10-13) versus 8.6 (6.6-11) versus 8.4 (6.9-10); non-CV death 2.4 (1.8-3.1) versus 3.3 (2.1-4.8) versus 4.5 (3.5-5.9); all-cause hospitalization 48 (45-51) versus 35 (31-40) versus 42 (39-46); HF hospitalization 29 (27-32) versus 19 (16-22) versus 17 (15-20); and non-CV hospitalization 7.7 (6.6-8.9) versus 9.6 (7.5-12) versus 15 (13-17). Conclusion: In AHF, HFrEF is more severe and has greater in-hospital mortality. Post-discharge, HFrEF has greater CV risk, HFpEF greater non-CV risk, and HFmrEF lower overall risk.
Palabras chave
Heart failure with mid-range ejection fraction
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Hospitalization
Prognosis
Treatment
 
Versión do editor
https://doi.org/10.1002/ejhf.2408
Dereitos
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
ISSN
1388-9842

Ítems relacionados

Mostrando ítems relacionados por Título, autor ou materia.

  • Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry 

    Bonapace, Stefano; Rossi, Andrea; Laroche, Cécile; Crespo-Leiro, María Generosa; Piepoli, Massimo F.; Coats, Andrew J. S.; Dahlström, Ulf; Malek, Filip; Macarie, Cezar; Temporelli, Pier Luigi; Maggioni, Aldo P.; Tavazzi, Luigi (Willey Online Library, 2019-12-09)
    [Abstract] Aims To investigate the still uncertain independent prognostic impact of pulse pressure (PP) in acute heart failure (HF), in particular across the left ventricular ejection fraction (EF) phenotypes, and the ...
  • Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use 

    Papp, Zoltán; Álvarez, Julián; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Černý, Vladimir; Comín-Colet, Josep; Crespo-Leiro, María Generosa; Delgado Jiménez, Juan Francisco; Édes, István; Eremenko, Alexander; Farmakis, Dimitrios; Fedele, Francesco; Fonseca, Cândida; Fruhwald, Sonja; Girardis, Massimo; Guarracino, Fabio; Harjola, Veli-Pekka; Heringlake, Matthias; Herpain, Antoine; Heunks, Leo; Husebye, Tryggve; Ivancan, Višnja; Karason, Kristjan; Kaul, Sundeep; Kivikko, Matti; Kubica, Janek; Masip, Josep; Matskeplishvili, Simon; Mebazaa, Alexandre; Nieminen, Markku S.; Oliva, Fabrizio; Papp, Julius G.; Parissis, John; Parkhomenko, Alexander; Põder, Pentti; Pölzl, Gerhard; Reinecke, Alexander; Ricksten, Sven-Erik; Riha, Hynek; Rudiger, Alain; Sarapohja, Toni; Schwinger, Robert H. G.; Toller, Wolfgang; Tritapepe, Luigi; Tschöpe, Carsten; Wikström, Gerhard; Lewinski, Dirk von; Vrtovec, Bojan; Pollesello, Piero; Agostoni, Piergiuseppe (Wolters Kluwer, 2020-07)
    [Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ...
  • Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: a review 

    Pascual-Figal, Domingo; Bayes-Genis, A.; Beltrán-Troncoso, Paola; Caravaca-Pérez, Pedro; Conde-Martel, Alicia; Crespo-Leiro, María Generosa; Delgado Jiménez, Juan Francisco; Díez, Javier; Formiga, Francesc; Manito, Nicolás (Frontiers, 2021-11-11)
    [Abstract] Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a ...

Listar

Todo RUCComunidades e colecciónsPor data de publicaciónAutoresTítulosMateriasGrupo de InvestigaciónTitulaciónEsta colecciónPor data de publicaciónAutoresTítulosMateriasGrupo de InvestigaciónTitulación

A miña conta

AccederRexistro

Estatísticas

Ver Estatísticas de uso
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Suxestións